Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 25, Issue 8, 2006, Pages 713-720

  Tejedor, Juan C ^a   Moro, Manuel ^b   Ruiz Contreras, Jesus ^c   Castro, Javier ^c   Gómez Campderá, Jose A ^d   Navarro, Maria Luisa ^d   Merino, Jose Manuel ^e   Martín Ancel, Ana ^f   Roca, Joan ^g   García Del Río, Manuel ^h   Jurado, Antonio ^h   Díez Delgado, Francisco Javier ⁱ   Omeñaca, Felix ^j   García Sicilia, Jose ^j   Boceta, Reyes ^k,l   García Corbeira, Pilar ^k,l   Jacquet, Jeanne Marie ^k,l   Collard, Alix ^k,l   Schuerman, Lode ^k,l  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^f HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^g HOSPITAL SANT JOAN DE DÉU   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ HOSPITAL TORRECÁRDENAS   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k GLAXOSMITHKLINE   (Spain)

^l GlaxoSmithKline ^*

more..

Author keywords

Coadministration; DTaP HBV IPV Hib vaccine; Meningococcal C conjugate vaccine; Primary immunization

Indexed keywords

ANTIBODY; ANTIGEN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; NEIS VAC C; POLIOMYELITIS VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; BIRTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEWBORN; NORMAL HUMAN; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN REDNESS; TETANUS;

ANALYSIS OF VARIANCE; DIPHTHERIA; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MENINGOCOCCAL VACCINES; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; SPAIN; TETANUS; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 33746765741     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000227725.61495.c4     Document Type: Article

References (30)

1. Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep. 2002;51(RR-2):1-35.
2. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol. 2002;67:433-439.
3. Schmitt HJ, Knuf M, Ortiz E, et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr. 2000;137:304-312.
4. Avdicová M, Prikazský V, Hudecková H, et al. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr. 2002;161:581-587.
5. Arístegui J, Dal-Ré R, Díez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine. 2003;21:3593-3600.
6. Capiau C, Poolman J, Hoet B, Bogaerts H, Andre F. Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned. Vaccine. 2003;21:2273-2287.
7. Gabutti G, Zepp F, Schuerman L, et al. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis. 2004;36:585-592.
8. Zepp F, Knuf M, Heininger U, et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine. 2004;22:2226-2233.
9. Nolan T, Altmann A, Skeljo M, Streeton C, Schuerman L. Antibody persistence, PRP-specific immune memory and booster responses in infants immunized with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine. 2004;23:14-20.
10. rd annual meeting of the European Society of Paediatric Infectious Diseases (ESPID), Valencia, 2005: abstract.
11. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51:717-722.
12. Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health. 2002;5:220-225.
13. Cano R, Larrauri A, Mateo S, Alcala B, Salcedo C, Vazquez J. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill. 2004;9:5-6.
14. De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA. 2004;292:2491-2494.
15. Andre FE. Development and clinical application of new polyvalent combined paediatric vaccines. Vaccine. 1999;17:1620-1627.
16. Bogaerts H. The future of childhood immunizations: examining the European experience. Am J Manag Care. 2003;9(1 suppl):S30-36.
17. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(1 suppl):S6-12.
18. Tejedor JC, Omeñaca F, Garcia-Sicilia J, et al. Immunogenicity and reactogenicity of a 3-dose primary vaccination course with a combined diphtheria-tetanus-3 component acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine co-administered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J. 2004;23:1109-1115.
19. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immunol. 2001;69:1568-1573.
20. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786.
21. Trotter CL, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 2003;21:1094-1098.
22. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diag Lab Immunol. 2001;8:616-623.
23. st annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), Taormina, Italy, 2003: abstract 169.
24. Granoff DM, Holmes SJ, Belshe RB, Osterholm MT, McHugh JE, Anderson EL. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA. 1994;272:1116-1121.
25. Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine. 1993;11(suppl 1):S46-51.
26. Castillo de Febres O, Decker MD, Estopinan M, Bordones G, Edwards KM. Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 1994;13:635-639.
27. Kurikka S. Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine. 1996;14:1239-1242.
28. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced responses to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immunol. 1998;66:2093-2098.
29. Pichichero ME, Blatter MM, Reisinger KS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J. 2002;21:854-859.
30. nd annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), Tampere, Finland, 2004: abstract 290.